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Abstract
Published data supports the neuroprotective effects of several phenolic-containing natural 
products, including certain fruit, berries, spices, nuts, green tea, and olive oil. However, limited 
data are available for phenolic-containing plant-derived natural sweeteners including maple syrup. 
Herein, we investigated the neuroprotective effects of a chemically standardized phenolic-enriched 
maple syrup extract (MSX) using a combination of biophysical, in vitro, and in vivo studies. Based 
on biophysical data (Thioflavin T assay, transmission electron microscopy, circular dichroism, 
dynamic light scattering, and zeta potential), MSX reduced amyloid β1–42 peptide (Aβ1–42) 
fibrillation in a concentration-dependent manner (50–500 μg/mL) with similar effects as the 
neuroprotective polyphenol, resveratrol, at its highest test concentration (63.5% at 500 μg/mL vs. 
77.3% at 50 μg/mL, respectively). MSX (100 μg/mL) decreased H2O2-induced oxidative stress 
(16.1% decrease in ROS levels compared to control), and down-regulated the production of 
lipopolysaccharide (LPS)-stimulated inflammatory markers (22.1, 19.9, 74.8, and 87.6% decrease 
in NOS, IL-6, PGE2, and TNFα levels, respectively, compared to control) in murine BV-2 
microglial cells. Moreover, in a non-contact co-culture cell model, differentiated human SH-SY5Y 
neuronal cells were exposed to conditioned media from BV-2 cells treated with MSX (100 μg/mL) 
and LPS or LPS alone. MSX-BV-2 media increased SH-SY5Y cell viability by 13.8% compared 
to media collected from LPS-BV-2 treated cells. Also, MSX (10 μg/mL) showed protective effects 
against Aβ1–42 induced neurotoxicity and paralysis in Caenorhabditis elegans in vivo. These data 
support the potential neuroprotective effects of MSX warranting further studies on this natural 
product.
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Introduction
Microglia cells are resident immune cells in the central nervous system which can be 
activated by abnormalities including oxidative and inflammatory stresses [1]. Chronic 
activation of microglia cells leads to the production of pro-inflammatory cytokines including 
nitric oxide synthase (NOS), interleukins, prostaglandins (PGs), and tumor necrosis factor α 
(TNFα) [2]. These neurotoxic inflammatory factors result in massive neuronal cell death and 
are linked to several neurodegenerative diseases including Alzheimer’s disease (AD), a 
progressive neurodegenerative disease [3]. AD is the most common cause of dementia and 
will afflict 11% of the United States population over the age of 65 costing the nation $226 
billion in 2015 alone [4]. It is estimated that by 2050, the worldwide incidence of AD will 
triple unless innovative strategies, including dietary intervention, are implemented in 
addition to lifestyle changes and chronic disease management [5].
The extensive neuronal loss that leads to functional and memory impairments in AD patients 
has been attributed to the proteotoxicity of extracellular amyloid-beta (Aβ) plaques and 
intracellular tau neurofibrillary tangles [6, 7]. Several pharmacological therapies focus on 
interrupting the underlying pathogenesis of AD in the brain [8]. While a common target is 
Aβ plaques, these approaches have largely been unsuccessful due to limitations in current 
scientific understanding of all of the etiological and pathophysiological factors relevant in 
AD. Therefore, there is a critical need to discover new therapeutic approaches to manage 
AD, especially since several drugs currently in clinical evaluation have been associated with 
severe side effects in patients [9]. Consequently, similar to several other chronic human 
diseases, the integration of natural products as part of a non-toxic dietary intervention 
strategy holds great promise for AD prevention [10]. This is due, in part, to the multi-
mechanistic modes of action exerted by natural compounds, whereby, they could potentially 
prevent and/or delay the deleterious effects of oxidative stress, neuroinflammation, 
proteotoxicity, and other factors implicated in the pathogenesis of neurodegenerative 
diseases.
Published data suggest that several phenolic-rich plant foods including certain fruits, berries, 
spices, nuts, green tea, and olive oil may show promise for AD prevention [10]. Phenolic 
compounds include a chemically diverse group of secondary metabolites containing a 
phenolic moiety which are prevalent in plant foods and their derived products. Indeed, 
dietary plant extracts and their purified phenolic constituents such as resveratrol (from grape 
and red wine) [10], anthocyanins (from berries) [11], curcumin (from turmeric spice) [12], 
oleocanthal (from olive oil) [13], and catechin (from grape seed) [14], have been studied 
extensively for their biological effects against AD. Several studies have noted that the 
biological activities of these single purified molecules are potentiated by synergistic, 
additive, and/or complementary effects of multiple (minor) constituents present in their 
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respective phenolic-enriched ‘whole’ plant extracts [15]. Thus, chemically standardized 
botanical extracts, delivered in food, supplement, and pharmaceutical matrices, hold great 
promise for the prevention of neurodegenerative diseases in future human clinical studies.
Maple syrup is a plant-derived natural sweetener obtained by boiling the sap collected 
primarily from the sugar maple (Acer saccharum) species. Apart from its predominant 
constituent which is sucrose, maple syrup also contains oligosaccharides, amino acids, 
organic acids, vitamins, minerals, and phytohormones [16]. In addition, a large number of 
natural phenolic compounds originally present in the xylem sap of the sugar maple plant 
survive the boiling process and persist in maple syrup [16–19]. However, despite the wide 
consumption of maple syrup worldwide, and knowledge that it contains a diverse array of 
phenolic constituents (over fifty phenolics belonging to lignan, stilbene, flavonoid, 
coumarin, and phenolic acid sub-classes have been isolated and identified from maple syrup) 
[17–19, 22], studies evaluating their health promoting effects are very limited. Moreover, 
based on our knowledge to date, few studies have been conducted to evaluate the 
neuroprotective effects of this natural sweetener [20, 21]. In one of those studies, a phenolic-
enriched maple syrup extract was shown to decrease oligomerization and aggregation of 
both Aβ1–42 and tau peptides, which are proteins involved in AD pathogenesis [20]. In light 
of the aforementioned factors, and given the paucity of data on the neuroprotective effects of 
natural plant-derived sweeteners, including maple syrup, we designed the current study.
Our group has previously reported on the chemical standardization of a food grade phenolic-
enriched maple syrup extract (named MSX) for nutraceutical applications [22]. This extract 
contains the natural phenolic constituents, as well as other substances (amino acids, organic 
acids, minerals, and oligosaccharides) present in the whole maple syrup food but with 
reduced sucrose content. MSX is well tolerated and its safety has been established in animal 
studies (in Sprague-Dawley rats) [22]. Notably, MSX shows anti-inflammatory effects 
(based on in vitro studies in RAW264.7 macrophages) superior to any of its purified 
phenolic constituents alone [23]. Therefore, given the aforementioned factors about the 
additive and synergistic effects observed with ‘whole’ plant extracts [15], as well as the 
possibility of a nutraceutical/botanical supplement being utilized as a dietary intervention 
strategy in future human clinical studies, we have chosen to advance our studies on this 
natural product by evaluating MSX rather than any of its purified single constituents alone.
Herein, we sought to evaluate the neuroprotective effects of MSX against AD using a 
combination of biophysical (Thioflavin T assay, transmission electron microscopy, circular 
dichroism, dynamic light scattering, and zeta potential), in vitro (in murine BV-2 microglial, 
and human SY-SY5Y neuronal cells) and in vivo (in Caenorhabditis elegans) studies. This is 
the first study to evaluate the effects of maple syrup constituents on markers of oxidative and 
inflammatory stresses in brain cells and its potential to delay Aβ1–42 induced neurotoxicity 
and paralysis in an in vivo AD model.
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Materials and Methods
Chemicals
Human amyloid peptide 1–42 (Aβ1–42) was purchased from AnaSpec (Fremont, CA, USA). 
Resveratrol (RESV), Folin-Ciocalteu reagent, thioflavin T (ThT), 2′,7′-dichlorofluorescin 
diacetate (DCFDA), lipopolysaccharide (LPS) and solvents were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Uranyl acetate was purchased from Structure Probe Inc. 
(West Chester, PA, USA). ELISA kits for prostaglandin E2 (PGE2), and tumor necrosis 
factor α (TNFα) and interleukin-6 (IL-6) were purchased from Cayman Chemical (Ann 
Arbor, MI, USA), and Abcam (Cambridge, MA, USA), respectively.
Phenolic-enriched maple syrup extract (MSX)
The phenolic-enriched maple syrup extract (MSX), was prepared according to our 
previously reported methods [19, 22, 23]. The details of the MSX preparation and its 
chemical characterization (by HPLC-DAD analyses by comparison to authentic phenolic 
standards previously isolated from maple syrup), the structures of the compounds identified 
therein, and the carbohydrate (sucrose, glucose and fructose) and phenolic (by Folin-
Ciocalteu assay based on gallic acid equivalents, GAEs) contents, are provided in the 
Supplementary Materials.
Aβ1–42 thioflavin T (ThT) binding assay
Aβ1–42 solutions were prepared following previously reported methods with minor 
modifications [24]. In brief, fibril formation was induced by incubating 50 μM Aβ1–42 
solutions at 37 °C for 5 d. Treatment included MSX at varying concentrations (50, 100, 200 
and 500 μg/mL) and the widely studied neuroprotective polyphenolic compound, resveratrol 
(RESV), used as the positive control (at 50 μg/mL). The ThT binding assay was used to 
evaluate Aβ1–42 fibrillation by adding ThT solution (200 μL) at a concentration of 10 μM to 
each sample (50 μL). The intrinsic fluorescence was immediately measured using a Spectra 
Max M2 spectrometer (Molecular Devices, Sunnyvale, CA, USA) at excitation and emission 
wavelengths of 450 and 483 nm, respectively. Percent inhibition (% inhibition) of each 
treatment was calculated based on arbitrary ﬂuorescence (FU) by the following equation: % 
inhibition = [(FU of control − FU of treatment)/FU of control] × 100%.
Transmission electron microscope (TEM) analyses
Aβ1–42 solutions for TEM analysis were prepared under the same conditions as the ThT 
binding assay. Aβ1–42 fibril formation was visualized by TEM as previously reported [25, 
26]. The blank, control, and MSX (500 μg/mL) treated samples (5 μL each) were placed 
onto a 200 mesh carbon-coated copper TEM grid (Ted Pella Inc., Redding, CA, USA) for 2 
min. The excess fluid was removed by filter paper and 5% uranyl acetate (10 μL) was placed 
onto the grid for 2 min. Aβ1–42 fibril formation was imaged using a Joel Corp. (Peabody, 
MA, USA) JEM 2100 TEM with a LaB6 illumination filament operating at 200 kV.
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Circular dichroism (CD) analyses
The change in the secondary structure of Aβ solutions were measured using a Jasco J-1100 
CD spectropolarimeter (Jasco, Tokyo, Japan). Analyzed samples included 50 μM native 
Aβ1–42 solution (non-incubated) and the aforementioned fibril-enriched Aβ solutions. CD 
measurements were carried out in the far-ultraviolet region from 190–260 nm using a quartz 
cuvette with a path length of 0.1 cm. The bandwidth was set at 1 nm for each run and 5 
repetitive scans were obtained. The Selcon 3 method was applied to calculate the secondary 
structure composition using CDPro software (Jasco, Tokyo, Japan).
Dynamic light scattering (DLS) and zeta potential measurement
The size of Aβ1–42 aggregates and zeta potential were measured with a Zetasizer Nano-
ZS90 (Malvern, Worcestershire, UK) as previously reported for the analyses of amyloid 
fibril formation [27]. Test samples included: 1) 50 μM freshly prepared Aβ1–42, 2) 50 μM 
Aβ1–42 aggregated at 37 °C for 5 d and, 3) 50 μM aggregated Aβ1–42 co-treated with MSX 
(500 μg/mL) for 5 d. Each measurement represents the average of three independent 
experiments and 100 consecutive runs were obtained for each sample at an operating 
temperature of 25 °C.
Cell culture
The BV-2 murine microglial cells were a gift from Dr. Grace Y. Sun (University of Missouri 
at Columbia, MO, USA) and the SH-SY5Y (human neuroblastoma) cells were obtained 
from the American Type Culture Collection (ATCC). Cell lines were maintained using high 
glucose (4.5 g/L) DMEM/F12 (Life Technologies, Gaithersburg, MD, USA) supplemented 
with 10% heat inactivated FBS (Life Technologies, Gaithersburg, MD, USA), 1% P/S (100 
U/ml penicillin, 100 μg/ml streptomycin) (Life Technologies, Gaithersburg, MD, USA) and 
incubated in 5% CO2 at 37°C. After reaching a confluency of 85%, the SH-SY5Y cells were 
differentiated for 7 d using all-trans retinoic acid (10 μM) while changing media every 48 h 
to ensure proper neurite growth and cell morphology. All samples were dissolved in DMSO 
(Sigma Aldrich, St. Louis, MO, USA) to yield a 10 mg/mL stock solution. Samples were 
further diluted to yield solutions with a final DMSO concentration of less than 0.1%.
Measurement of cell viabilities
Cell viabilities of BV-2 and SH-SY5Y cells were evaluated using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric assay [28] and 
CellTiter-Glo 2.0 (CTG 2.0) one step assay (Promega Fitchburg, WI, USA), respectively. 
Briefly, in the MTT assay, BV-2 cells were seeded into 48-well plates at a density of 104 
cells/well in DMEM. After 24 h, the cells were treated with MSX (50 or 100 μg/mL) for 48 
h. At the end of the treatment, the cell viability was measured by using cell-counting kit 8 
reagent (Dojindo Molecular Technologies, Rockville, MD, USA), according to the 
manufacturer’s instructions. In the CTG 2.0 assay, SH-SY5Y cells were seeded at 10−5 
cells/mL to yield 80–85% confluency in a standard white walled clear bottom 96-well plate 
after 24 h initial incubation. Following a secondary incubation period (24 h), CTG 2.0 was 
added in a 1:1 ratio with the existing media in the wells and mixed for 2 min on an orbital 
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shaker prior to luminescence measurement using the Spectramax M2 (Molecular Devices 
Sunyvale, CA, USA).
Measurement of levels of reactive oxygen species (ROS)
BV-2 cells were seeded into 48-well plates at a density of 104 cells/well in DMEM. After 24 
h, the cells were pretreated with MSX (50 or 100 μg/mL) or the positive control, resveratrol 
(RESV; 5 μg/mL) for 24 h. Then, the medium was replaced with DMEM containing 20 μM 
DCFDA for 20 min. The cells were washed with phosphate buffered saline and incubated 
with H2O2 at a non-toxic concentration (3.0 μg/mL) for 1 h. The fluorescence signal was 
read at excitation and emission wavelengths of 485 and 525 nm, respectively, using a 
Spectra Max M2 spectrometer (Molecular Devices, Sunnyvale, CA, USA).
Measurement of nitric oxide species (NOS) levels by Griess assay
BV-2 microglial cells in 24-well plates (n = 4) at 85% confluency (105 cells/well) were 
serum-starved for 4 h prior to the treatments. Then the cells were incubated with MSX (50 
or 100 μg/mL) or the positive control, resveratrol (RESV; 5 μg/mL) for 1 h before 
lipopolysaccharide (LPS) was added. After 23 h incubation, the cell culture media were 
collected and centrifuged. The supernatants were measured for total nitric oxide (NO) levels 
using the Griess assay kit (Promega, Fitchburg, WI, USA) as previously reported [23]. 
Sodium nitrite, at different dilutions, was used to generate a standard curve which was used 
to calculate nitrite concentrations.
Measurements of IL-6, PGE2, and TNFα levels
Supernatants collected from the NO experiments above were collected and assayed for 
inflammatory cytokines including interleukin-6 (IL-6), prostaglandin E2 (PGE2) and tumor 
necrosis factor α (TNFα). Quantification of PGE2 and TNFα were measured using enzyme 
linked immunosorbent assay (ELISA) kits based on the respective manufacturer protocols.
Non-contact co-culture model with BV-2 and SH-SY5Y cells
BV-2 and SH-SY5Y cells were co-cultured as previously reported [29–31]. Briefly, BV-2 
and differentiated SH-SY5Y cells (both cell lines at a density of 105 cells/mL) were plated 
in 12-well and 96-well plates, respectively, and allowed to attach for 24 h. The BV-2 cells 
were then exposed to MSX (50 and 100 μg/mL) or RESV (5 μg/mL; positive control) for 1 h 
prior to exposure to LPS (1 μg/mL) for a duration of 24 h of treatment. Conditioned media 
were then collected from the BV-2 cells and centrifuged at 18,000 rcf for 5 min at 4°C. The 
media from the SH-SY5Y cells was removed and replaced with the centrifuged conditioned 
media from the BV-2 cells and left to incubate for 24 h after which they were subjected to 
the CTG 2.0 assay to assess cell viability.
Transgenic Caenorhabditis elegans in vivo assay
The C. elegans nematode assay was carried out as previously reported by our group [24]. 
Briefly, the transgenic C. elegans strain CL4176, developed to express human amyloid β1–42 
in the muscle tissue in response to heat shock, were obtained from the Caenorhabditis 
Genetics Center (CGC) (University of Minnesota, Minneapolis, MN, USA). Worms were 
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grown and maintained at 16 °C on 60 mm culture plates with Nematode Growth Medium 
(NGM). Media was poured aseptically into culture plates (10 mL for 60 mm) using a 
peristaltic pump and allowed to solidify for 36 h. NGM culture plates were then inoculated 
with 50 μL of Escherichia coli OP50 (CGC, University of Minnesota, Minneapolis, MN, 
USA) overnight cultures and incubated for 8 h at 37 °C. The C. elegans were maintained by 
picking 2–3 young adult worms onto freshly inoculated NGM plates every 4–7 d. MSX was 
dissolved in S-basal buffer and methanol solution (1:1; v/v) and further diluted in S-basal 
buffer to a yield a final concentration of 1 mg/mL which served as the stock solution. The 
MSX stock solution was added directly to the NGM media for a final treatment 
concentration of 10 μg/mL. Upon development of the eggs to the L3 larval stage, the 
incubation temperature of the plates was increased from 16 to 25 °C to induce the expression 
of Aβ1–42. Mobility scoring was conducted beginning at 20 h after the temperature increase 
and continued in 2 h increments until all of the worms were paralyzed. Failure to respond to 
touch (prodding with a worm pick) and, absence of pharyngeal pumping, were used to score 
paralyzed/dead worms.
Statistical analyses
Data are presented as mean ± standard deviation of at least 3 separate experiments. For the 
ThT assay, statistical analysis was conducted by one-way factorial ANOVA with Tukey-
Kramer post hoc comparisons. Cellular assay data were expressed as means ± standard 
errors. P values were generated using ANOVA followed by Dunnett’s test for multiple 
comparisons of group means. For the in vivo C. elegans assay, the Kaplan-Meier method 
was used to compare the lifespan survival curves and the survival differences were tested for 
statistical significance using the Log rank test (Mantel Cox). Significance for all tests was 
defined as: p≤0.05 (*), p≤0.01 (**), p≤0.001 (***), and p≤0.0001 (****). GraphPad Prism 
software 6.0 (GraphPad Software, Inc., San Diego, CA) was used for all statistical analysis 
calculations.
Results and discussion
Chemical characterization of phenolic-enriched maple syrup extract (MSX)
MSX is a chemically standardized food grade phenolic-enriched maple syrup extract, 
previously developed by our group for nutraceutical applications, with established safety and 
tolerability data in animals [22]. For the present study, MSX was prepared in our laboratory 
based on methods previously reported by our group (details provided in Supplementary 
Materials).
Our group has previously isolated and identified (using NMR and mass spectrometry) over 
fifty phenolic compounds from maple syrup [19, 22, 23]. Therefore, through comparison of 
HPLC-DAD retention times with these chemical marker standards, as shown in Fig. 1, a 
total of thirty-seven compounds (chemical structures provided in Fig. S2 in the 
Supplementary Materials) were identified in MSX. As expected, the majority of the 
compounds in MSX are phenolic compounds, belonging to lignan, coumarin, phenolic acid, 
and stilbene sub-classes.
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The phenolic content of MSX used in the present study was determined as 24.0% (based on 
gallic acid equivalents, GAEs). In addition, it had a sucrose content of ca. 10.0% as 
compared to pure maple syrup which was 63%. The levels of fructose and glucose in MSX 
were < 0.1%. We next sought to evaluate the neuroprotective effects of MSX using a 
combination of biophysical (Thioflavin T assay, transmission electron microscopy, circular 
dichroism, dynamic light scattering and zeta potential), in vitro (murine BV-2 microglial, 
and human SH-SY5Y cells) and in vivo (Caenorhabditis elegans) studies (further described 
below).
MSX inhibits Aβ fibrillation
Aβ deposition in brain leads to the formation of senile plaques and causes neurotoxicity in 
AD patients. During the progression of AD, soluble unstructured Aβ peptides gradually 
reassemble to insoluble Aβ fibrils, a structure enriched in β-sheet confirmation. Therefore, 
MSX was evaluated for its inhibitory effects on the formation of Aβ1–42 fibril structures 
using a combination of biophysical methods. Aβ1–42 fibrillation was first quantified by the 
fluorescence based ThT binding assay (Fig. 2A) and the morphology of the fibrils was 
visualized by TEM (Fig. 2B). The β-sheet contents were measured by circular dichroism 
(CD) studies (Fig. 3). The size and zeta potential of Aβ1–42 aggregates were measured by 
zetasizer (Table 1).
As shown in Fig. 2A, the control generated the highest binding level in the ThT assay 
indicating that the control group had the highest level of Aβ1–42 fibrillation. The Aβ1–42 
fibrillation level significantly decreased in all of the treatment samples including the 
different concentrations of MSX (from 50–500 μg/mL) and the neuroprotective polyphenolic 
compound, resveratrol (RESV), used as a positive control. The data generated in the current 
study for RESV (50 μg/mL, inhibition = 77.3%, p≤0.001) is in agreement with previously 
published data [32]. Similarly, the MSX treated solutions showed a concentration-dependent 
effect at 500, 250, 100 and 50 μg/mL, reducing Aβ fibrillation by 63.5, 55.9, 54.9 and 
18.9%, respectively. Therefore, the ThT assay data suggested that both MSX and RESV 
significantly inhibited Aβ fibrillation. Also, it should be noted that the lowest test 
concentration of MSX (50 μg/mL) significantly inhibited the formation of Aβ1–42 fibrils 
(p≤0.05).
Our findings from the ThT assay were further confirmed by the TEM analyses. As shown in 
Fig. 2B, the control Aβ1–42 sample generated morphology of aggregates typically seen in the 
fibrillation process of Aβ1–42 [25, 26]. In contrast, the Aβ1–42 co-treated with MSX (500 
μg/mL) sample showed a different morphology compared to the control. The overall fibrils 
in the MSX treated solution were significantly less dense but more amorphous, indicating 
that the formation of highly ordered Aβ fibrils was reduced by MSX.
Next, we measured the β-sheet contents in Aβ1–42 solutions using CD spectroscopy (shown 
in Fig. 3 and Table 1). Compared to native non-aggregated Aβ1–42, all of the incubated 
samples displayed a signature dip at 220 nm, indicating the formation of β-sheets structures 
[33]. However, in the MSX treated sample (500 μg/mL), the conformational changes of the 
β-sheets were 10% lower than that of control (49.6 vs. 59.6%). A similar trend was observed 
for the positive control, RESV (50 μg/mL), which showed a β-sheet content of 46.7%.
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Aβ1–42 fibrillation can cause the formation of aggregates which can be measured by 
dynamic light scattering (DLS) [27]. Based on DLS measurements (shown in Table 1), no 
measurable aggregates were observed in native freshly prepared Aβ1–42. In contrast, after 
incubation at 37 °C, Aβ1–42 yielded aggregates with particle size of 317.9 nm and a 
dominant content of 86.4% which were reduced to 39.84 nm and 77%, respectively, by MSX 
(500 μg/mL). As previously reported, the zeta potential of Aβ1–42 shifts to a more negative 
value as aggregation progresses [27]. Our data is in agreement with these observations [27] 
wherein we observed a significant decrease in zeta potential values from −4.58 mV for 
freshly prepared Aβ1–42 to −22.4 mV for aggregated Aβ1–42. However, the MSX treated 
Aβ1–42, generated an increase in zeta potential value of −17.6 mV, indicating that the 
aggregation process was less extensive than the control.
Taken together, the biophysical data from the ThT assay, TEM analyses, CD experiment, 
DLS, and zeta potential measurements suggested that the MSX treatments effectively 
inhibited Aβ1–42 structural transformation from soluble non-toxic peptides to insoluble 
neuro-toxic fibrils. These data are in agreement with the previous report for a phenolic-
enriched maple syrup extract [20]. However, to date, no previous studies have been 
conducted to evaluate the neuroprotective effects of maple syrup in brain cells or in an in 
vivo AD model; therefore, we proceeded with the following experiments (described below).
MSX protects murine BV-2 microglia against H2O2-induced oxidative stresses in vitro
Microglia cells are resident innate immune cells in the central nervous system with a similar 
functional role as macrophages. An important cellular response in neurodegenerative 
diseases pathogenesis is microglial activation. Moreover, the over-activation of microglia 
can lead to the release of a variety of pro-inflammatory mediators which are potentially 
neurotoxic. This activation process is often promoted by cellular oxidative stress factors 
including reactive oxygen species (ROS) and thus, the reduction of ROS levels alleviates 
microglial activation and related neuronal disorders [34]. Therefore, MSX was evaluated (at 
non-toxic concentrations, ranging from 10 to 100 μg/mL based on the MTT assay, as shown 
in Fig. 4A) for its effects on H2O2 (3.0 μg/mL) induced ROS production in murine BV-2 
microglia cells. As shown in Fig. 4B, MSX decreased H2O2-induced ROS production in 
BV-2 cells. At concentrations of 50 and 100 μg/mL, MSX reduced H2O2-induced ROS 
production by 9.9 and 16.1%, respectively. The positive control, RESV, decreased H2O2-
induced ROS levels by 66.2% at a concentration of 5 μg/mL, which was similar to 
previously reported data [34].
MSX protects murine BV-2 microglia against LPS-induced inflammatory stresses in vitro
Our group has previously shown that MSX reduced pro-inflammatory cytokines in 
RAW264.7 murine macrophages [23] but to date, these effects have not been investigated in 
brain cells. Herein, we evaluated whether MSX could reduce levels of biomarkers for 
neuronal inflammation, induced by LPS, in BV-2 cells. Indeed, the LPS treated cells 
produced higher NO levels compared to untreated cells (51.9 vs 9.2 μM). As shown in Fig. 
5A, MSX inhibited NO production. At 50 and 100 μg/mL, MSX decreased NO production 
by 10.0 and 22.1%, respectively. Similar to previously reported data [34], RESV (5 μg/mL), 
reduced LPS-induced NO production by 23%.
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Next, MSX was further evaluated for its effects on inflammatory cytokines, IL-6, PGE2 and 
TNFα, in the BV-2 cells. As shown in Fig. 2A, after incubation of the BV-2 microglial cells 
with LPS, MSX (100 μg/mL) significantly (by 19.9%) reduced IL-6 levels as compared to 
the LPS treated control cells. However, the IL-6 production was not significantly (4.2 %) 
reduced by treatment of MSX at the lower concentration of 50 μg/mL. The levels of PGE2 
were reduced by 52.9 and 74.8%, after treatment with 50 and 100 μg/mL MSX, respectively, 
compared to LPS treated control cells, In comparison, the positive control, RESV (5 μg/mL), 
reduced PGE2 levels by 22.5% which was similar to previously reported data [34] (Fig. 5C). 
Similarly, the levels of TNFα were down-regulated by treatment of BV-2 cells with MSX 
(Fig. 5D) by 75.2 and 87.6%, after treatment with 50 and 100 μg/mL MSX, respectively, 
compared to the LPS treated cells. The positive control, RESV (5 μg/mL), decreased TNFα 
levels by 31.4% similar to previously reported data [34].
MSX reduces cytotoxicity of human SH-SY5Y neuronal cells after exposure to murine BV-2 
microglia conditioned media
Co-culture systems have been employed to investigate the impact of microglia and its 
inflammatory mediators on the cell death of neurons [29–31, 35]. Therefore, we used a non-
contact cell culture model (using conditioned media) to evaluate the protective effects of 
MSX against neurotoxicity (induced by inflammatory biomarkers released by LPS-
stimulated BV-2 microglia) of differentiated human SH-SY5Y neuronal cells as previously 
reported [30, 31]. As shown in Fig. 6, media from BV-2 cells (treated with LPS alone) 
significantly decreased (15.0%) the cell viability of differentiated SH-SY5Y neuronal cells. 
On the contrary, the conditioned media from BV-2 cells treated with MSX (at 100 and 50 
μg/mL) reduced SH-SY5Y neuronal cell death by 17.7 and 13.8%, respectively. The positive 
control, RESV (5 μg/mL), decreased the SH-SY5Y neuronal cell death by 30.5%. This 
observation indicated that MSX was able to ameliorate microglia-mediated neuronal cell 
death possibly by decreasing the production of inflammatory biomarkers by the microglia.
MSX protects Aβ1–42 induced neurotoxicity and paralysis in Caenorhabditis elegans in vivo
We next evaluated the effects of MSX in an established C. elegans in vivo model of AD [24]. 
The mobility curves for the C. elegans CL4176 strain after the Aβ1–42 induction of muscular 
paralysis at 25 °C are shown in Fig. 6. Compared to the control worms (Fig. 7A), treatment 
with 10 μg/mL MSX did not have any significant effect on the median survival/mobility in 
C. elegans post induction of Aβ1–42 induced neurotoxicity and paralysis. However, MSX 
treatment (Fig. 7B) significantly increased the maximum survival/mobility by 3.0% and 
decreased the mean survival/mobility post induction of Aβ1–42 induced neurotoxicity and 
paralysis by 10.4% (as shown in Table 2).
Mitochondrial dysfunction, inflammation, oxidative stress, and activation of apoptotic 
signaling due to intra- and extracellular accumulation of misfolded or damaged proteins has 
been linked to the etiopathology of neurodegenerative diseases, including AD [36, 37]. 
Therefore, therapies that specifically target mediators of proteotoxicity and inflammation 
may be more successful in ameliorating neurodegenerative processes [38]. The transgenic 
AD model of C. elegans used in our study specifically measures the intracellular aggregation 
of the Aβ1–42 peptide in muscle tissues and permits investigation of inflammatory and 
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proteotoxicity contributors of Aβ1–42 peptide aggregation and subsequent neuromuscular 
paralysis [24, 39, 40]. In response to treatment with MSX, the heat-shock induced 
aggregation of Aβ1–42 peptide and resultant paralysis was significantly delayed in the C. 
elegans model. These results corroborated our observations from the biophysical and in vitro 
studies wherein MSX reduced Aβ1–42 fibrillation, oxidative stress, and inflammatory 
cytokines. It is possible that the reduced proteotoxicity in C. elegans in response to MSX 
could be due to the presence of certain bioactive compounds that interacts with 
amyloidogenic proteins to prevent their oligomerization (and thus aggregation) [41]. 
However further studies would be required to confirm this. Overall, the current study with 
MSX support studies done with other natural products including coffee bean extract [42], 
Ginkgo biloba [41], curcumin, and several tropical fruit extracts [39, 40], suggesting similar 
mechanism/s for reducing Aβ1–42 aggregation by abrogating proteotoxicity and 
inflammation.
Conclusion
In summary, using a combination of biophysical, in vitro, and in vivo studies, a phenolic-
enriched extract of maple syrup (MSX) was shown to reduce Aβ1–42 fibrillation and 
decrease oxidative and inflammatory stresses in murine BV-2 microglial cells and SHSY-5Y 
neuronal cells. Furthermore, MSX imparted protective effects on Aβ1–42 aggregation 
induced neurotoxicity and paralysis in C. elegans. However, further in vivo studies to 
confirm the neuroprotective effects of MSX, and to predict a human equivalent consumption 
dose, are necessary given that the current data does not account for important physiological 
considerations such as bioavailability and metabolism. Nevertheless, these findings add to 
recently published data supporting the potential neuroprotective effects of maple syrup [20, 
21], warranting further studies on this natural plant-derived sweetener.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Aβ1–42 amyloid peptide 1–42
DCFDA 2′,7′-dichlorofluorescin diacetate
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RESV resveratrol
DMEM/F12 Dulbecco’s modified eagle medium: nutrient mixture F-12
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Fig. 1. 
HPLC-DAD chromatogram of a phenolic-enriched maple syrup extract (MSX) showing 37 
compounds identified as follows: (1) 4-hydroxy-2-(hydroxymethyl)-5-methyl-3(2H)-
furanone, (2) 3,4-dihydro-5-(hydroxymethyl)pyran-2-one, (3) 5-(hydroxymethyl)furfural, 
(4) 2-hydroxy-3,4-dihydroxyacetophenone, (5) 4-(hydroxymethyl)-1,2-benzenediol, (6) 
catechol, (7) C-veratroylglycol, (8) threo,threo-1-[4-(2-hydroxy-2-(4-hydroxy-3-
methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3-propanetriol, (9) 2,3-
dihydroxy-1-(4-hydroxy-3,5-dimethoxyphenyl)-1-propanone, (10) 4-acetylcatechol, (11) 
tyrosol, (12) catechaldehyde, (13) 1,2-diguaiacyl-1,3-propanediol, (14) 3′,5′-dimethoxy-4′-
hydroxy-2-hydroxyacetophenone, (15) leptolepisol D, (16) 3,4-dihydroxy-2-
methylbenzadehyde, (17) vanillin, (18) fraxetin, (19) syringaldehyde, (20) syringenin, (21) 
scopoletin, (22) threo-guaiacylglycerol-β-O-4′-dihydroconiferyl alcohol, (23) erythro-
guaiacylglycerol-β-O-4′-dihydroconiferyl alcohol, (24) 5-(3″,4″-dimethoxyphenyl)-3-
hydroxy-3-(4′-hydroxy-3′-methoxybenzyl)-4-(hydroxymethyl) dihydrofuran-2-one, (25) 1-
(2,3,4-trihydroxy-5-methylphenyl)ethanone, (26) erythro-1-(4-hydroxy-3-
methoxyphenyl)-2-[4-(3-hydroxypropyl)-2,6-dimethoxyphenoxy]-1,3-propanediol, (27) 
icariside E4, (28) 3′,4′,5′-trihydroxyacetophenone, (29) dehydroconiferyl alcohol, (30) 
sakuraresinol, (31) secoisolariciresinol, (32) acernikol, (33) (1S,2R)-2-[2,6-dimethoxy-4-
[(1S,3aR,4S,6aR)-tetrahydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1H,3H-furo[3,4-
c]furan-1-yl]phenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol, (34) 2-[4-[2,3-
dihydro-3-(hydroxymethyl)-5-(3-hydroxypropyl)-7-methoxy-2-benzofuranyl]-2,6-
dimethoxyphenoxy]-1-(4-hydroxy-3-methoxyphenyl)-1,3-propanediol, (35) 4,4′-
dihydroxy-3,3′,5,5′-tetramethoxystilbene, (36) 4,4′-dihydroxy-3,3′,5′-trimethoxystilbene, 
and (37) (E)-3,3′-dimethoxy-4,4′-dihydroxystilbene.
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Fig. 2. 
(A) ThT binding assay showing the levels of Aβ1–42 aggregation treated with different 
concentrations of MSX (50–500 μg/mL) or positive control resveratrol (RESV; at 50 μg/
mL); (B) TEM analyses of Aβ1–42 solution freshly mixed with 500 μg/mL MSX without 
incubation (left), Aβ1–42 solution incubated for 5 d (middle) and Aβ1–42 solution co-treated 
with 500 μg/mL MSX then incubated for 5 d (right).
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Fig. 3. 
Circular dichroism (CD) measurement of native Aβ, aggregated Aβ, and Aβ co-treated with 
MSX (500 ug/mL).
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Fig. 4. 
MSX reduced H2O2-induced oxidative stress in BV-2 murine microglial cells. (B) BV-2 cells 
were pretreated with MSX (50 or 100 μg/mL) for 24 h followed by 1 h of H2O2 (3 μg/mL) 
treatment. The H2O2-induced ROS production was measured by using the DCFDA reagent.
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Fig. 5. 
BV-2 cells pretreated with MSX (50 or 100 μg/mL) for 1 h followed by exposure to LPS (1 
μg/mL) for 24 h. The treated cell culture media were used to assay the amount of NOS (A), 
IL-6 (B), PGE2 (C), and TNFα (D) production. Resveratrol (RESV, at 5 μg/mL) served as 
the positive control for all the assays. Data are presented as means ± SDs of three 
independent experiments.
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Fig. 6. 
MSX reduced murine BV-2 microglia-mediated neurotoxicity of human SH-SY5Y neuron 
cells. BV-2 cells were treated with MSX (50 and 100 μg/mL) or resveratrol (RESV, 5 
μg/mL; positive control) for 1 h prior to exposure to LPS (1 μg/mL) for 24 h. The 
conditioned media from the BV-2 were collected and added to SH-SY5Y cells. After 
incubation for 24 h, cell viability of SH-SY5Y cells were measured by the CTG 2.0 assay. 
All data points were compared to the LPS column.
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Fig. 7. 
Mobility curves of transgenic (CL4176) C. elegans 20 h post Aβ1–42 induction of muscular 
paralysis at 25 °C. Kaplan-Meier mobility plots of C. elegans worms fed on (A) Control 
(NGM); (B) MSX: (NGM + 10 μg/mL MSX).
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Table 1
Measurement of zeta potential, particle size distribution, and β-sheet content of native Aβ1–42, aggregated 
Aβ1–42 and MSX (500 μg/mL) treated Aβ1–42. (n.d. = not detected)
Native Aβ1–42 Aggregated Aβ1–42 MSX (500 μg/mL)
Zeta Potential (mV) −4.58 −22.4 −17.6
Particle Size (d.nm) n.d. 317.9 (86.4%)3.088 (13.6%)
39.84 (77.0%)
4.838 (23.0%)
β-sheet content (%) 18.8 59.6 49.6
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Table 2
Survival (mean, median, and maximum) of (CL4176) C. elegans worms treated with MSX (10 μg/mL) post 
Aβ1–42 induction of muscular paralysis at 25 °C.
Treatment
(10 μg/mL)
Survival time (h)
Mean Median Maximum
Control (n>1000) 29.60 26.00 30.27
MSX (n>1000) 26.50* 26.00 31.20*
*p< 0.05; Log rank test (Mantel Cox).
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